Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada finds no BPA risks in formula

This article was originally published in The Tan Sheet

Executive Summary

A Canadian survey of bisphenol A in canned powdered infant formulas determines the chemical used in the internal coating of food containers "is not expected to pose a health risk to the general population, including newborns and infants." Health Canada analyzed 38 formula products -- including Similac and Isomil from Abbott Labs, Enfamil from Mead Johnson and Good Start from Nestle -- and found BPA concentration below the average method detection limit of 0.13 nanograms per gram in all samples, according to a July report. One ng/g is equivalent to 1 part per billion. The report says FDA agrees with the Canadian agency's health risk conclusions, though Congress wants FDA to reassess BPA risks as part of pending food safety legislation (1"The Tan Sheet" June 22, 2009)

You may also be interested in...



BPA Study Added To Food Safety Bill, But Supplements Remain “Gray Area”

The House Energy and Commerce Committee added a requirement that FDA reassess bisphenol A risks before approving a food safety reform bill

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel